OBJECTIVES: Prostate cancer treatment should depend on the characteristics of a patient's prostate cancer as well as overall health status. A possible adverse consequence of poor patient selection is a lack of benefit because of premature death from another cause. We evaluated the association between perioperative comorbidity and risk of death from causes other than prostate cancer in men who underwent radical prostatectomy (RP). METHODS: We conducted a retrospective cohort study of 14,052 men who underwent RP from 1983 to 2006. The Charlson Comorbidity Index (CCI) score was calculated using the discharge records for the prostatectomy hospitalization. Mortality status and cause of death were obtained via chart review and searches of national databases. Cox proportional hazards regression was used to estimate the hazard ratio (HR) of death from causes other than prostate cancer after RP by CCI score (0, 1, 2+). RESULTS: The median age at RP was 58.1 years. The median follow-up was 7.6 years (interquartile range 4.3-11.5). Of 849 deaths, 599 (70.6%) resulted from causes other than prostate cancer. On multivariable analysis, men with a CCI ≥2 had a statistically significantly higher risk of death from causes other than prostate cancer compared with those with lower CCI scores (HR 2.18, 95% CI 1.30-3.64, P = .0003). CONCLUSIONS: Greater perioperative comorbidity was associated with a higher risk of death from causes other than prostate cancer in men who underwent RP. Physicians should consider using a standardized tool to assess perioperative comorbidities to enhance appropriate recommendation for surgical treatment.
OBJECTIVES:Prostate cancer treatment should depend on the characteristics of a patient's prostate cancer as well as overall health status. A possible adverse consequence of poor patient selection is a lack of benefit because of premature death from another cause. We evaluated the association between perioperative comorbidity and risk of death from causes other than prostate cancer in men who underwent radical prostatectomy (RP). METHODS: We conducted a retrospective cohort study of 14,052 men who underwent RP from 1983 to 2006. The Charlson Comorbidity Index (CCI) score was calculated using the discharge records for the prostatectomy hospitalization. Mortality status and cause of death were obtained via chart review and searches of national databases. Cox proportional hazards regression was used to estimate the hazard ratio (HR) of death from causes other than prostate cancer after RP by CCI score (0, 1, 2+). RESULTS: The median age at RP was 58.1 years. The median follow-up was 7.6 years (interquartile range 4.3-11.5). Of 849 deaths, 599 (70.6%) resulted from causes other than prostate cancer. On multivariable analysis, men with a CCI ≥2 had a statistically significantly higher risk of death from causes other than prostate cancer compared with those with lower CCI scores (HR 2.18, 95% CI 1.30-3.64, P = .0003). CONCLUSIONS: Greater perioperative comorbidity was associated with a higher risk of death from causes other than prostate cancer in men who underwent RP. Physicians should consider using a standardized tool to assess perioperative comorbidities to enhance appropriate recommendation for surgical treatment.
Authors: Michael Froehner; Rainer Koch; Rainer J Litz; Sven Oehlschlaeger; Oliver W Hakenberg; Manfred P Wirth Journal: Eur Urol Date: 2005-02 Impact factor: 20.096
Authors: Jochen Walz; Nazareno Suardi; Shahrokh F Shariat; Claudio Jeldres; Paul Perrotte; Markus Graefen; Hughes Widmer; Philippe Arjane; Luc Valiquette; Georg Hutterer; Fred Saad; Pierre I Karakiewicz Journal: BJU Int Date: 2008-04-02 Impact factor: 5.588
Authors: Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning Journal: J Natl Cancer Inst Date: 2003-06-18 Impact factor: 13.506
Authors: Magnus Törnblom; Henry Eriksson; Stefan Franzén; Ove Gustafsson; Hans Lilja; Ulf Norming; Jonas Hugosson Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Kah Poh Loh; Mazie Tsang; Thomas W LeBlanc; Anthony Back; Paul R Duberstein; Supriya Gupta Mohile; Ronald M Epstein; Heidi D Klepin; Michael W Becker; Areej El-Jawahri; Stephanie J Lee Journal: Blood Adv Date: 2020-11-10
Authors: Heather J Chalfin; Steven M Frank; Zhaoyong Feng; Bruce J Trock; Charles G Drake; Alan W Partin; Elizabeth Humphreys; Paul M Ness; Byong C Jeong; Seung B Lee; Misop Han Journal: Transfusion Date: 2014-03-06 Impact factor: 3.157
Authors: Pierre Lunardi; Guillaume Ploussard; Pascale Grosclaude; Mathieu Roumiguié; Michel Soulié; Jean Baptiste Beauval; Bernard Malavaud Journal: World J Urol Date: 2016-07-21 Impact factor: 4.226
Authors: Raina Shivashankar; Sahil Khanna; Patricia P Kammer; W Scott Harmsen; Alan R Zinsmeister; Larry M Baddour; Darrell S Pardi Journal: Clin Gastroenterol Hepatol Date: 2013-05-20 Impact factor: 11.382
Authors: R Shivashankar; S Khanna; P P Kammer; W Scott Harmsen; A R Zinsmeister; L M Baddour; D S Pardi Journal: Aliment Pharmacol Ther Date: 2014-07-10 Impact factor: 8.171